Quick Answer
SANGAMO THERAPEUTICS, INC reported Stockholders Equity of -$14.27 million for fiscal year 2025.
SANGAMO THERAPEUTICS, INC Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | -$14.27M | -162.7% |
| 2024 | $22.77M | -72.5% |
| 2023 | $82.89M | -71.9% |
| 2022 | $294.96M | -21.4% |
| 2021 | $375.34M | -24.7% |
| 2020 | $498.23M | +15.2% |
| 2019 | $432.55M | +18.0% |
| 2018 | $366.52M | +95.1% |
| 2017 | $187.90M | +38.0% |
| 2016 | $136.19M | -29.2% |
| 2015 | $192.44M | -6.9% |
| 2014 | $206.63M | +69.8% |
| 2013 | $121.71M | +87.5% |
| 2012 | $64.90M | -19.0% |
| 2011 | $80.13M | +43.3% |
| 2010 | $55.91M | -22.1% |
| 2009 | $71.78M | +29.6% |
| 2008 | $55.40M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $6.24M | -84.0% | -68.2% |
| June 30, 2025 | $19.60M | -17.3% | +299.6% |
| March 31, 2025 | $4.91M | -91.3% | -78.5% |
| December 31, 2024 | $22.77M | -72.5% | -41.8% |
| September 30, 2024 | $39.13M | -71.0% | +65.2% |
| June 30, 2024 | $23.69M | -89.9% | -58.2% |
| March 31, 2024 | $56.70M | -83.1% | -31.6% |
| December 31, 2023 | $82.89M | -71.9% | -38.6% |
- SANGAMO THERAPEUTICS, INC showed a decrease of -162.7% in Stockholders Equity compared to the prior fiscal year.
- Over the 2008–2025 period, SANGAMO THERAPEUTICS, INC’s stockholders equity has declined by 125.8% (from $55.40 million to -$14.27 million).
- The most recent figure is from SANGAMO THERAPEUTICS, INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: